A weight-loss drug taken by millions is showing an unexpected gift: it appears to lift depression, but not in the way scientists expected. Researchers at Southeast University have discovered that liraglutide—marketed as Victoza and Saxenda—alleviates depressive symptoms not by acting directly on the brain, but by reshaping the bacteria in the gut, triggering a cascade of molecular benefits that calm stress-related brain activity.
This finding resolves a long-standing scientific puzzle. Some clinical studies reported that GLP-1 drugs reduced depression, while others suggested they increased anxiety risk. The prevailing assumption was straightforward: these medications must be working directly on GLP-1 receptors scattered throughout the brain. But the new research, published in Cell Host & Microbe, points to an alternative pathway that is far more indirect and, in some ways, more elegant.
Yonggui Yuan and his team at Southeast University set out to test this mystery in mouse models exposed to stress. When they administered liraglutide systemically, they found something surprising: the drug accumulated predominantly in the intestine, not the brain. This observation prompted a bold hypothesis. To test whether the drug's antidepressant effects actually depended on direct brain action, the researchers genetically knocked out GLP-1 receptors in the brains of mice. The drug still worked. The antidepressant activity persisted, suggesting an entirely different mechanism was at play.
The breakthrough came when the team depleted the gut microbiota of mice using broad-spectrum antibiotics. Without their microbial communities, liraglutide lost its antidepressant effects entirely. This pointed directly to bacteria as the crucial intermediary. Studying fecal samples from treated mice, the researchers identified which microbes were shifting: Lactobacillus delbrueckii increased most significantly in response to liraglutide.
This species of bacteria holds a molecular secret. Lactobacillus delbrueckii produces diacylglycerol, a precursor that the body converts into 2-arachidonoylglycerol (2-AG), a molecule known to calm hyperactivation in brain regions associated with stress. The researchers found that the abundance of L. delbrueckii directly correlated with behavioral improvements in their models—the more of this beneficial bacterium, the greater the mood lift.
What emerges is a striking chain of causation: a metabolic drug taken for weight loss reshapes the gut microbiome, one particular bacterial species expands, it produces a precursor molecule, that molecule becomes an endocannabinoid, and this endocannabinoid normalizes activity in stress-related brain regions. Depression lifts, not because the drug touched the brain directly, but because it orchestrated a microbial conversation about mood regulation.
The implications stretch across medicine. Patients with both metabolic disorders like diabetes and obesity and concurrent depression could potentially benefit from a single treatment. The finding also opens doors to probiotic interventions—targeted bacterial therapies designed to replicate liraglutide's mood-boosting effects without the drug itself.
The researchers acknowledge important limitations. This work was conducted in male mice, not humans, and depression manifests differently across sexes. Whether this gut-brain mechanism operates identically in women remains an open question. Yet the core insight stands: the pathway to mood regulation may run through the microbiome, and metabolic drugs may be rewriting our mental health in ways we're only beginning to understand.